+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sale

Global Bleeding Disorder Treatment Market (2021-2026) by Type, Drug Class, Distribution Channel, Geography, Competitive Analysis and the Impact of Covid-19 with Ansoff Analysis

  • PDF Icon

    Report

  • 180 Pages
  • September 2021
  • Region: Global
  • Infogence Global Research
  • ID: 5503424
UP TO OFF until Sep 30th 2022
The Global Bleeding Disorder Treatment Market is estimated to be USD 13.5 Bn in 2021 and is expected to reach USD 18.6 Bn by 2026, growing at a CAGR of 10%.



Market Dynamics

The factors driving the growth of the bleeding disorder treatment market are the rise in the prevalence of liver disorders, anemia, and other blood coagulation disorders. The increasing awareness of the bleeding disorders treatment and improving healthcare infrastructure in developing countries will also fuel the scope of market growth. Furthermore, the rising R&D investment for the development of hemophilia products is anticipated to boost the bleeding disorder treatment market.

However, the lack of reimbursement policies, lack of skilled professionals and trained experts are hampering the market growth. Also, the absence of access to proper treatment due to the high cost of medication is restraining the market growth. Growth in the awareness for bleeding disorders treatment is generating lucrative growth opportunities.

Market Segmentation

The Global Bleeding Disorder Treatment Market is segmented further based on Type, Drug Class, Distribution Channel, and Geography.

By Type, the market is classified into Hemophilia A, Hemophilia B, Von Willebrand Disease (vWD), and Others. Amongst all, the Hemophilia A segment is estimated to hold the highest market share during the forecast period.

By Drug Class, the market is classified as Plasma Derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrate, Desmopressin Acetate, Antifibrinolytics, Fibrin Sealants, and Others. Amongst all, the Recombinant Coagulation Factor Concentrate segment is estimated to hold the highest market share during the forecast period.

By Distribution Channel, the market is classified as Hospitals, Clinics, Research Institutes, and Others. Amongst all, the Hospital segment is estimated to hold the highest market share during the forecast period.

By Geography, North America is projected to lead the market.

Recent Developments

1. Novo Nordisk had announced ESPEROCT [antihemophilic factor (recombinant), glycopegylated-exei] which was launched in the U.S. for the treatment of adults and children with hemophilia. - 10th February 2020
2. Bayer AG agreed to a three-year collaboration with the children’s hospital. The development of small molecules to treat hemophilia A and B is the main motto of collaboration. - 5th December 2019

Company Profiles

Some of the companies covered in this report are Amgen Inc., BDI Pharma Inc., Johnson & Johnson, Pfizer Inc., Sanofi S.A., CSL Behring, Biogen Inc., Baxalta, etc.

Competitive Quadrant

The report includes Competitive Quadrant, a proprietary tool to analyze and evaluate the position of companies based on their Industry Position score and Market Performance score. The tool uses various factors for categorizing the players into four categories. Some of these factors considered for analysis are financial performance over the last 3 years, growth strategies, innovation score, new product launches, investments, growth in market share, etc.

Why buy this report?

  • The report offers a comprehensive evaluation of the Global Bleeding Disorder Treatment Market. The report includes in-depth qualitative analysis, verifiable data from authentic sources, and projections about market size. The projections are calculated using proven research methodologies.
  • The report has been compiled through extensive primary and secondary research. The primary research is done through interviews, surveys, and observation of renowned personnel in the industry.
  • The report includes an in-depth market analysis using Porter’s 5 forces model and the Ansoff Matrix. In addition, the impact of Covid-19 on the market is also featured in the report.
  • The report also includes the regulatory scenario in the industry, which will help you make a well-informed decision. The report discusses major regulatory bodies and major rules and regulations imposed on this sector across various geographies.
  • The report also contains the competitive analysis using Positioning Quadrants, the analyst’s Proprietary competitive positioning tool.

Report Highlights:

  • A complete analysis of the market, including parent industry
  • Important market dynamics and trends
  • Market segmentation
  • Historical, current, and projected size of the market based on value and volume
  • Market shares and strategies of key players
  • Recommendations to companies for strengthening their foothold in the market
Frequently Asked Questions about the Global Bleeding Disorder Treatment Market

What is the estimated value of the Global Bleeding Disorder Treatment Market?

The Global Bleeding Disorder Treatment Market was estimated to be valued at $13500 Million in 2021.

What is the growth rate of the Global Bleeding Disorder Treatment Market?

The growth rate of the Global Bleeding Disorder Treatment Market is 6.6%, with an estimated value of $18600 Million by 2026.

What is the forecasted size of the Global Bleeding Disorder Treatment Market?

The Global Bleeding Disorder Treatment Market is estimated to be worth $18600 Million by 2026.

Who are the key companies in the Global Bleeding Disorder Treatment Market?

Key companies in the Global Bleeding Disorder Treatment Market include Alnylam Pharmaceuticals Inc., Alexion Pharmaceuticals (A Subsidiary of AstraZeneca), Amgen Inc., Bayer AG, Biogen Inc., Bristol, Myers Squibb, Johnson & Johnson and Sanofi S.A..

Table of Contents

1 Report Description
1.1 Study Objectives
1.2 Market Definition
1.3 Currency
1.4 Years Considered
1.5 Language
1.6 Key Stakeholders
2 Research Methodology
2.1 Research Process
2.2 Data Collection and Validation
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 IGR Models
2.3 Market Size Estimation
2.3.1 Bottom-Up Approach
2.3.2 Top-Down Approach
2.4 Assumptions of the Study
2.5 Limitations of the Study
3 Executive Summary
3.1 Introduction
3.2 Market Size and Segmentation
3.3 Market Outlook
4 Market Influencers
4.1 Drivers
4.1.1 Rising Prevalence of Liver Disease and Anaemia
4.1.2 Increasing Health Care Expenditure due to Rise in Disposable Income
4.1.3 Increasing Awareness Regarding Bleeding Disorders
4.1.4 Rising R&D Investment for Development of Hemophilia Products
4.2 Restraints
4.2.1 High Cost of Investment
4.2.2 Stringent Government Regulations
4.3 Opportunities
4.3.1 Growing Healthcare Infrastructure in Emerging Countries
4.3.2 Rising R&D Investment for Development of Haemophilia Products
4.3.3 Growing Biosimilar Products Market Local Partnerships in Pharma-emerging Countries
4.4 Challenges
4.4.1 Lack of Favourable Reimbursement Policies
4.5 Trends
5 Market Analysis
5.1 Regulatory Scenario
5.2 Porter’s Five Forces Analysis
5.3 Impact of COVID-19
5.4 Ansoff Matrix Analysis
6 Global Bleeding Disorder Treatment Market, By Type
6.1 Introduction
6.2 Hemophilia A
6.3 Hemophilia B
6.4 Von Willebrand Disease (VWD)
6.5 Others
7 Global Bleeding Disorder Treatment Market, By Drug Class
7.1 Introduction
7.2 Plasma Derived Coagulation Factor Concentrates
7.3 Recombinant Coagulation Factor Concentrates
7.4 Desmopressin Acetate
7.5 Antifibrinolytics
7.6 Fibrin Sealants
7.7 Others
8 Global Bleeding Disorder Treatment Market, By Treatment
8.1 Introduction
8.2 Desmopressin (DDAVP),
8.3 Hormone Replacement Therapy
8.4 Contraceptives
8.5 Anti-Fibrinolytic/Clot-Stabilizing Drugs
8.6 Fibrin Sealants
8.7 Drugs Applied To Cuts
8.8 Pipeline Analysis (Phase I, Phase II And Phase III Clinical Trials)
9 Global Bleeding Disorder Treatment Market, By Distribution Channel
9.1 Introduction
9.2 Hospital
9.3 Clinics
9.4 Research Institutes
9.5 Others
10 Global Bleeding Disorder Treatment Market, By Geography
10.1 Introduction
10.2 North America
10.2.1 US
10.2.2 Canada
10.2.3 Mexico
10.3 South America
10.3.1 Brazil
10.3.2 Argentina
10.3.3 Chile
10.3.4 Colombia
10.4 Europe
10.4.1 UK
10.4.2 France
10.4.3 Germany
10.4.4 Italy
10.4.5 Spain
10.4.6 Netherlands
10.4.7 Sweden
10.4.8 Russia
10.4.9 Rest of Europe
10.5 Asia-Pacific
10.5.1 China
10.5.2 Japan
10.5.3 India
10.5.4 Indonesia
10.5.5 Malaysia
10.5.6 South Korea
10.5.7 Australia
10.5.8 Sri Lanka
10.5.9 Thailand
10.5.10 Rest of APAC
10.6 Middle-East and Africa
10.6.1 Qatar
10.6.2 Saudi Arabia
10.6.3 South Africa
10.6.4 United Arab Emirates
11 Competitive Landscape
11.1 IGR Competitive Quadrant
11.2 Market Share Analysis
11.3 Strategic Initiatives
11.3.1 M&A and Investments
11.3.2 Partnerships and Collaborations
11.3.3 Product Developments and Improvements
12 Company Profiles
12.1 Alnylam Pharmaceuticals Inc.
12.2 Alexion Pharmaceuticals (A Subsidiary of AstraZeneca)
12.3 Amgen Inc.
12.4 Bayer AG
12.5 Biogen Inc.
12.6 Bristol-Myers Squibb
12.7 Johnson & Johnson
12.8 Pfizer Inc.
12.9 Sanofi S.A.
12.10 Xenetic Biosciences Inc.
12.11 CSL Behring
12.12 Grifols, S.A.
12.13 Octapharma Plasma, Inc.
12.14 Takeda Pharmaceutical Company
12.15 Kedrion Biopharma Inc.
12.16 Sun Pharma Industries Limited
12.17 Baxalta
12.18 Teva Pharmaceutical Industries Ltd
12.19 Dimension Therapeutics Inc.
12.20 Novo Nordisk A/S
12.21 BDI Pharma Inc.
12.22 Ferring Pharmaceuticals
12.23 Catalyst Biosciences
13 Appendix
13.1 Questionnaire

Companies Mentioned

  • Alnylam Pharmaceuticals Inc.
  • Alexion Pharmaceuticals (A Subsidiary of AstraZeneca)
  • Amgen Inc.
  • Bayer AG
  • Biogen Inc.
  • Bristol-Myers Squibb
  • Johnson & Johnson
  • Pfizer Inc.
  • Sanofi S.A.
  • Xenetic Biosciences Inc.
  • CSL Behring
  • Grifols, S.A.
  • Octapharma Plasma, Inc.
  • Takeda Pharmaceutical Company
  • Kedrion Biopharma Inc.
  • Sun Pharma Industries Limited
  • Baxalta
  • Teva Pharmaceutical Industries Ltd
  • Dimension Therapeutics Inc.
  • Novo Nordisk A/S
  • BDI Pharma Inc.
  • Ferring Pharmaceuticals
  • Catalyst Biosciences